Silencing HoxA1 by Intraductal Injection of siRNA Lipidoid Nanoparticles Prevents Mammary Tumor Progression in Mice
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Silencing HoxA1 by Intraductal Injection of siRNA Lipidoid Nanoparticles Prevents Mammary Tumor Progression in Mice
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 6, Issue 217, Pages 217ra2-217ra2
Publisher
American Association for the Advancement of Science (AAAS)
Online
2014-01-02
DOI
10.1126/scitranslmed.3007048
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy
- (2013) Hamidreza Montazeri Aliabadi et al. JOURNAL OF CONTROLLED RELEASE
- Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer
- (2013) Ibrahim Tekedereli et al. Molecular Therapy-Nucleic Acids
- Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors
- (2012) Yong Soon Chun et al. BREAST CANCER RESEARCH AND TREATMENT
- A Feasibility Study of the Intraductal Administration of Chemotherapy
- (2012) S. M. Love et al. Cancer Prevention Research
- Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression
- (2012) J. L. Chen et al. CLINICAL CANCER RESEARCH
- Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
- (2012) Shin-ichiro Ohno et al. MOLECULAR THERAPY
- Current progress of siRNA/shRNA therapeutics in clinical trials
- (2011) John C. Burnett et al. Biotechnology Journal
- Atypical ductal hyperplasia: interobserver and intraobserver variability
- (2011) Rohit K Jain et al. MODERN PATHOLOGY
- Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer
- (2011) V. Stearns et al. Science Translational Medicine
- National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
- (2010) C. J. Allegra et al. JNCI-Journal of the National Cancer Institute
- Elimination Pathways of Systemically Delivered siRNA
- (2010) Yuanyu Huang et al. MOLECULAR THERAPY
- Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells
- (2010) M. S. Goldberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Knocking down barriers: advances in siRNA delivery
- (2009) Kathryn A. Whitehead et al. NATURE REVIEWS DRUG DISCOVERY
- Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis
- (2009) Y.-H. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
- (2008) Akin Akinc et al. NATURE BIOTECHNOLOGY
- Update on atypical epithelial hyperplasia and ductal carcinoma in situ
- (2008) Jean F. Simpson PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search